Enliven Therapeutics Inc
Follow $ELVN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ELVN by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ELVN moving today?
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ELVN overview
Related filings and maps
Congress activity in ELVN
No receipt-qualified Congressional disclosure is present for ELVN in the cached public ledger.
ELVN contract awards, year to date.
Public federal awards linked to this ticker.
ELVN lobbying filings, year to date.
Registered lobbying filings matched to Enliven Therapeutics Inc.